Metastasis: Cell-autonomous mechanisms versus contributions by the tumor microenvironment

Cellular and Molecular Life Sciences

Volumn 63, Issue 4, 2006, Pages 449-468

  Kopfstein, L ^a   Christofori, G ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Angiogenesis; Lymphangiogenesis; Metastasis; Tumor stroma; Tumorigenesis

Indexed keywords

CANCER GROWTH FACTOR; CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR RECEPTOR; INTEGRIN; PLASMINOGEN ACTIVATOR; RAPAMYCIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; UVOMORULIN;

BLOOD VESSEL; CANCER INVASION; CARCINOMA; CELL ADHESION; CELL MIGRATION; CELL POLARITY; DENDRITIC CELL; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; LYMPH VESSEL; MESENCHYME; METASTASIS; MICROENVIRONMENT; NATURAL KILLER CELL; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STROMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CELL POLARITY; ENDOTHELIAL CELLS; FIBROBLASTS; HUMANS; IMMUNITY, NATURAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33645088428     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-005-5296-8     Document Type: Review

References (249)

1. Chambers A. F., Groom A. C. and MacDonald I. C. (2002) Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2: 563-572
2. Crissman J. D. (1986) Tumor-host interactions as prognostic factors in the histologic assessment of carcinomas. Pathol. Annu. 21 Pt 1: 29-52
3. Pollard J. W. (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4: 71-78
4. Mueller M. M. and Fusenig N. E. (2004) Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4: 839-849
5. Cavallaro U. and Christofori G. (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 4: 118-132
6. Kobielak A. and Fuchs E. (2004) Alpha-catenin: at the junction of intercellular adhesion and actin dynamics. Nat. Rev. Mol. Cell. Biol. 5: 614-625
7. Hirohashi S. (1998) Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am. J. Pathol. 153: 333-339
8. Perl A. K., Wilgenbus P., Dahl U., Semb H. and Christofori G. (1998) A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392: 190-193
9. Grunert S., Jechlinger M. and Beug H. (2003) Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell. Biol. 4: 657-665
10. Tarin D., Thompson E. W. and Newgreen D. F. (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 65: 5996-6000; discussion 6000-5991
11. Thiery J. P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2: 442-454
12. Janda E., Lehmann K., Killisch I., Jechlinger M., Herzig M., Downward J. et al. (2002) Ras and TGF [beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell. Biol. 156: 299-313
13. Peinado H., Portillo F. and Cano A. (2004)Transcriptional regulation of cadherins during development and carcinogenesis. Int. J. Dev. Biol. 48: 365-375
14. Barrallo-Gimeno A. and Nieto M. A. (2005) The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132: 3151-3161
15. Sugimachi K., Tanaka S., Kameyama T., Taguchi K., Aishima S., Shimada M. et al. (2003) Transcriptional repressor snail and progression of human hepatocellular carcinoma. Clin. Cancer Res. 9: 2657-2664
16. Blanco M. J., Moreno-Bueno G., Sarrio D., Locascio A., Cano A., Palacios J. et al. (2002) Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 21: 3241-3246
17. Yook J. I., Li X. Y., Ota I., Fearon E. R. and Weiss S. J. (2005) Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem. 180: 11746-11748
18. Kang Y. and Massague J. (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277-279
19. Lu Z., Ghosh S., Wang Z. and Hunter T. (2003) Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499-515
20. Zhou B. P., Deng J., Xia W., Xu J., Li Y. M., Gunduz M. et al. (2004) Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6: 931-940
21. Strathdee G. (2002) Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin. Cancer Biol. 12: 373-379
22. Kamei T., Matozaki T., Sakisaka T., Kodama A., Yokoyama S., Peng Y. F. et al. (1999) Coendocytosis of cadherin and c-Met coupled to disruption of cell-cell adhesion in MDCK cells - regulation by Rho, Rac and Rab small G proteins. Oncogene 18: 6776-6784
23. Morali O. G., Delmas V., Moore R., Jeanney C., Thiery J. P. and Larue L. (2001) IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20: 4942-4950
24. Behrens J., Vakaet L., Friis R., Winterhager E., Van Roy F., Mareel M. M. et al. (1993) Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J. Cell. Biol. 120: 757-766
25. Fujita Y., Krause G., Scheffner M., Zechner D., Leddy H. E., Behrens J. et al. (2002) Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol. 4: 222-231
26. McCawley L. J., O'Brien P. and Hudson L. G. (1998) Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)- mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. J. Cell Physiol. 176: 255-265
27. Sahai E. and Marshall C. J. (2002) RHO-GTPases and cancer. Nat. Rev. Cancer 2: 133-142
28. Noren N. K., Arthur W. T. and Burridge K. (2003) Cadherin engagement inhibits RhoA via p190RhoGAP. J. Biol. Chem. 278: 13615-13618
29. Kuroda S., Fukata M., Nakagawa M., Fujii K., Nakamura T., Ookubo T. et al. (1998) Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin- mediated cell-cell adhesion. Science 281: 832-835
30. Noren N. K., Niessen C. M., Gumbiner B. M. and Burridge K. (2001) Cadherin engagement regulates Rho family GTPases. J. Biol. Chem. 276: 33305-33308
31. Itoh K., Yoshioka K., Akedo H., Uehata M., Ishizaki T. and Narumiya S. (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 5: 221-225
32. Clark E. A., Golub T. R., Lander E. S. and Hynes R. O. (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532-535
33. Sander E. E., van Delft S., ten Klooster J. P., Reid T., van der Kammen R. A., Michiels F. et al. (1998) Matrix-dependent Tiaml/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J. Cell. Biol. 143: 1385-1398
34. Cavallaro U., Niedermeyer J., Fuxa M. and Christofori G. (2001) N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat. Cell Biol. 3: 650-657
35. Suyama K., Shapiro I., Guttman M. and Hazan R. B. (2002) A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2: 301-314
36. Guo W. and Giancotti F. G. (2004) Integrin signalling during tumour progression. Nat. Rev. Mol. Cell. Biol. 5: 816-826
37. Hood J. D. and Cheresh D. A. (2002) Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2: 91-100
38. Hynes R. O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687
39. Friedl P. and Wolf K. (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 3: 362-374
40. Bissell M. J. and Radisky D. (2001) Putting tumours in context. Nat. Rev. Cancer 1: 46-54
41. Natali P. G., Hamby C. V., Felding-Habermann B., Liang B., Nicotra M. R., Di Filippo F. et al. (1997) Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 57: 1554-1560
42. Gingras M. C., Roussel E., Bruner J. M., Branch C. D. and Moser R. P. (1995) Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J. Neuroimmunol. 57: 143-153
43. Rolli M., Fransvea E., Pilch J., Saven A. and Felding-Habermann B. (2003) Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl. Acad. Sci USA 100: 9482-9487
44. Rabinovitz I. and Mercurio A. M. (1997) The integrin α6β4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin-containing motility structures. J. Cell. Biol. 139: 1873-1884
45. Maaser K., Wolf K., Klein C. E., Niggemann B., Zanker K. S., Brocker E. B. et al. (1999) Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol. Biol. Cell 10: 3067-3079
46. Ballestrem C., Hinz B., Imhof B. A. and Wehrle-Haller B. (2001) Marching at the front and dragging behind: differential alphaVbeta3-integrin turnover regulates focal adhesion behavior. J. Cell. Biol. 155: 1319-1332
47. Senger D. R., Perruzzi C. A., Streit M., Koteliansky V. E., de Fougerolles A. R. and Detmar M. (2002) The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration and tumor angiogenesis. Am. J. Pathol. 160: 195-204
48. Reynolds L. E., Wyder L., Lively J. C., Taverna D., Robinson S. D., Huang X. et al. (2002) Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 8: 27-34
49. Silletti S., Yebra M., Perez B., Cirulli V., McMahon M. and Montgomery A. M. (2004) Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J. Biol. Chem. 279: 28880-28888
50. Roesler J., Srivatsan E., Moatamed F., Peters J. and Livingston E. H. (1997) Tumor suppressor activity of neural cell adhesion molecule in colon carcinoma. Am. J. Surg. 174: 251-257
51. Tezel E., Kawase Y., Takeda S., Oshima K. and Nakao A. (2001) Expression of neural cell adhesion molecule in pancreatic cancer. Pancreas 22: 122-125
52. Perl A. K., Dahl U., Wilgenbus P., Cremer H., Semb H. and Christofori G. (1999) Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic beta tumor cells. Nat. Med. 5: 286-291
53. Crnic I., Strittmatter K., Cavallaro U., Kopfstein L., Jussila L., Alitalo K. et al. (2004) Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. Cancer Res. 64: 8630-8638
54. Izumi Y., Hirata M., Hasuwa H., Iwamoto R., Umata T., Miyado K. et al. (1998) A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. 17: 7260-7272
55. Thies A., Schachner M., Moll I., Berger J., Schulze H. J., Brunner G. et al. (2002) Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur. J. Cancer 38: 1708-1716
56. Calvo A., Xiao N., Kang J., Best C. J., Leiva I., Emmert-Buck M. R. et al. (2002) Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and downregulation of selenoprotein-P in mouse and human tumors. Cancer Res. 62: 5325-5335
57. Katayama M., Iwamatsu A., Masutani H., Furuke K., Takeda K., Wada H. et al. (1997) Expression of neural cell adhesion molecule L1 in human lung cancer cell lines. Cell Struct. Funct. 22: 511-516
58. Heiz M., Grunberg J., Schubiger P. A. and Novak-Hofer I. (2004) Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1: role of the L1 cytoplasmic domain. J. Biol. Chem. 279: 31149-31156
59. Fogel M., Huszar M., Altevogt P. and Ben-Arie A. (2004) L1 (CD171) as a novel biomarker for ovarian and endometrial carcinomas. Expert Rev. Mol. Diagn. 4: 455-462
60. Mechtersheimer S., Gutwein P., Agmon-Levin N., Stoeck A., Oleszewski M., Riedle S. et al. (2001) Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J. Cell. Biol. 155: 661-673
61. Thelen K., Kedar V., Panicker A. K., Schmid R. S., Midkiff B. R. and Maness P. F. (2002) The neural cell adhesion molecule L1 potentiates integrin-dependent cell migration to extracellular matrix proteins. J. Neurosci. 22: 4918-4931
62. Gutwein P., Stoeck A., Riedle S., Gast D., Runz S., Condon T. P. et al. (2005) Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin. Cancer Res. 11: 2492-2501
63. Gast D., Riedle S., Schabath H., Schlich S., Schneider A., Issa Y. et al. (2005) L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas. Int. J. Cancer 115: 658-665
64. Gavert N., Conacci-Sorrell M., Gast D., Schneider A., Altevogt P., Brabletz T. et al. (2005) L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J. Cell. Biol. 168: 633-642
65. Blume-Jensen P. and Hunter T. (2001) Oncogenic kinase signalling. Nature 411: 355-365
66. Maulik G., Shrikhande A., Kijima T., Ma P. C., Morrison P. T. and Salgia R. (2002) Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 13: 41-59
67. Rong S., Segal S., Anver M., Resau J. H., Vande Woude G. F. (1994) Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl. Acad. Sci USA 91: 4731-4735
68. Takayama H., LaRochelle W. J., Sharp R., Otsuka T., Kriebel P., Anver M. et al. (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci USA 94: 701-706
69. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G. F. (2003) Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. 4: 915-925
70. Peschard P., Fournier T. M., Lamorte L., Naujokas M. A., Band H., Langdon W. Y. et al. (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8: 995-1004
71. Giordano S., Bardelli A., Zhen Z., Menard S., Ponzetto C. and Comoglio P. M. (1997) A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc. Natl. Acad. Sci USA 94: 13868-13872
72. Khwaja A., Lehmann K., Marte B. M. and Downward J. (1998) Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem. 273: 18793-18801
73. Bardelli A., Basile M. L., Audero E., Giordano S., Wennstrom S., Menard S. et al. (1999) Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene 18: 1139-1146
74. Paumelle R., Tulasne D., Kherrouche Z., Plaza S., Leroy C., Reveneau S. et al. (2002) Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene 21: 2309-2319
75. Yu Y, Zhang Y. C., Zhang W. Z., Shen L. S., Hertzog P., Wilson T. J. et al. (2003) Ets1 as a marker of malignant potential in gastric carcinoma. World J. Gastroenterol. 9: 2154-2159
76. Takai N., Miyazaki T., Fujisawa K., Nasu K. and Miyakawa I. (2000) Expression of c-Ets1 is associated with malignant potential in endometrial carcinoma. Cancer 89: 2059-2067
77. Trusolino L., Bertotti A. and Comoglio P. M. (2001) A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107: 643-654
78. Isacke C. M. and Yarwood H. (2002) The hyaluronan receptor, CD44. Int. J. Biochem. Cell Biol. 34: 718-721
79. Orian-Rousseau V., Chen L., Sleeman J. P., Herrlich P. and Ponta H. (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16: 3074-3086
80. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M. et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8: 128-135
81. Harrison G. M., Davies G., Martin T. A., Jiang W. G. and Mason M. D. (2002) Distribution and expression of CD44 isoforms and Ezrin during prostate cancer-endothelium interaction. Int. J. Oncol. 21: 935-940
82. Crepaldi T., Gautreau A., Comoglio P. M., Louvard D. and Arpin M. (1997) Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J. Cell. Biol. 138: 423-434
83. Medico E., Gentile A., Lo Celso C., Williams T. A., Gambarotta G., Trusolino L. et al. (2001) Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res. 61: 5861-5868
84. Zohar R., Suzuki N., Suzuki K., Arora P., Glogauer M., McCulloch C. A. et al. (2000) Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J. Cell Physiol. 184: 118-130
85. Tuck A. B., Arsenault D. M., O'Malley F. P., Hota C., Ling M. C., Wilson S. M. et al. (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18: 4237-4246
86. Barton W. A., Himanen J. P., Antipenko A. and Nikolov D. B. (2004) Structures of axon guidance molecules and their neuronal receptors. Adv. Protein Chem. 68: 65-106
87. Conrotto P., Corso S., Gamberini S., Comoglio P. M. and Giordano S. (2004) Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23: 5131-5137
88. Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G., Barberis D. et al. (2002) The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol. 4: 720-724
89. Conrotto P., Valdembri D., Corso S., Serini G., Tamagnone L., Comoglio P. M. et al. (2005) Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105: 4321-4329
90. Ried S., Jager C., Jeffers M., Vande Woude G. F., Graeff H., Schmitt M. et al. (1999) Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J. Biol. Chem. 274: 16377-16386
91. Ma P. C., Maulik G., Christensen J. and Salgia R. (2003) c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 22: 309-325
92. Reya T. and Clevers H. (2005) Wnt signalling in stem cells and cancer. Nature 434: 843-850
93. Giles R. H., van Es J. H. and Clevers H. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653: 1-24
94. Fodde R., Smits R. and Clevers H. (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1: 55-67
95. Gottardi C. J., Wong E. and Gumbiner B. M. (2001) E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J. Cell. Biol. 153: 1049-1060
96. Stockinger A., Eger A., Wolf J., Beug H. and Foisner R. (2001) E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. J. Cell. Biol. 154: 1185-1196
97. Wong A. S. and Gumbiner B. M. (2003) Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J. Cell. Biol. 161: 1191-1203
98. Gottardi C. J. and Gumbiner B. M. (2004) Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes. J. Cell. Biol. 167: 339-349
99. Jamora C., DasGupta R., Kocieniewski P. and Fuchs E. (2003) Links between signal transduction, transcription and adhesion in epithelial bud development. Nature 422: 317-322
100. Guaita S., Puig I., Franci C., Garrido M., Dominguez D., Batlle E. et al. (2002) Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J. Biol. Chem. 277: 39209-39216
101. Mosesson Y. and Yarden Y. (2004) Oncogenic growth factor receptors: implications for signal transduction therapy. Semin. Cancer Biol. 14: 262-270
102. Schroeder J. A., Adriance M. C., McConnell E. J., Thompson M. C., Pockaj B. and Gendler S. J. (2002) ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J. Biol. Chem. 277: 22692-22698
103. Nelson W. J. and Nusse R. (2004) Convergence of Wnt, beta-catenin and cadherin pathways. Science 303: 1483-1487
104. Baserga R. (1999) The IGF-I receptor in cancer research. Exp. Cell Res. 253: 1-6
105. Jiang Y., Wang L., Gong W., Wei D., Le X., Yao J. et al. (2004) A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin. Exp. Metastasis 21: 755-764
106. Furukawa M., Raffeld M., Mateo C., Sakamoto A., Moody T. W., Ito T. et al. (2005) Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth and development of metastases. Clin. Cancer Res. 11: 3233-3242
107. Prakash S., Sarran L., Socci N., DeMatteo R. P., Eisenstat J., Greco A. M. et al. (2005) Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular and genomic study of 15 cases and review of the literature. J. Pediatr. Hematol. Oncol. 27: 179-187
108. Gydee H., O'Neill J. T., Patel A., Bauer A. J., Tuttle R. M. and Francis G. L. (2004) Differentiated thyroid carcinomas from children and adolescents express IGF-I and the IGF-I receptor (IGF-I-R). Cancers with the most intense IGF-I-R expression may be more aggressive. Pediatr. Res. 55: 709-715
109. Lopez T. and Hanahan D. (2002) Elevated levels of IGF-I receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1: 339-353
110. Garcia-Echeverria C., Pearson M. A., Marti A., Meyer T., Mestan J., Zimmermann J. et al. (2004) In vivo antitumor activity of NVP-AEW541-A novel, potent and selective inhibitor of the IGF-IR kinase. Cancer Cell 5: 231-239
111. Mitsiades C. S., Mitsiades N. S., McMullan C. J., Poulaki V., Shringarpure R., Akiyama M. et al. (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies and solid tumors. Cancer Cell 5: 221-230
112. Guvakova M. A. and Surmacz E. (1999) The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas and paxillin. Exp. Cell Res. 251: 244-255
113. Hermanto U., Zong C. S., Li W. and Wang L. H. (2002) RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol. Cell Biol 22: 2345-2365
114. Mauro L., Salerno M., Morelli C., Boterberg T., Bracke M. E. and Surmacz E. (2003) Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J. Cell Physiol. 194: 108-116
115. Morali O. G., Jouneau A., McLaughlin K. J., Thiery J. P. and Larue L. (2000) IGF-II promotes mesoderm formation. Dev. Biol. 227: 133-145
116. Derynck R. and Zhang Y. E. (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584
117. Attisano L. and Wrana J. L. (2002) Signal transduction by the TGF-beta superfamily. Science 296: 1646-1647
118. Watanabe H., de Caestecker M. P. and Yamada Y. (2001) Transcriptional cross-talk between Smad, ERK1/2 and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells. J. Biol. Chem. 276: 14466-14473
119. Bakin A. V., Tomlinson A. K., Bhowmick N. A., Moses H. L. and Arteaga C. L. (2000) Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275: 36803-36810
120. Hay E., Lemonnier J., Fromigue O. and Marie P. J. (2001) Bone morphogenetic protein-2 promotes osteoblast apoptosis through a Smad-independent, protein kinase C-dependent signaling pathway. J. Biol. Chem. 276: 29028-29036
121. Siegel P. M. and Massague J. (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 3: 807-821
122. Derynck R., Akhurst R. J. and Balmain A. (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29: 117-129
123. Oft M., Akhurst R. J. and Balmain A. (2002) Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol. 4: 487-494
124. Bhowmick N. A., Ghiassi M., Bakin A., Aakre M., Lundquist C. A., Engel M. E. et al. (2001) Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 12: 27-36
125. Bernards R. and Weinberg R. A. (2002) A progression puzzle. Nature 418: 823
126. Paris P. L., Andaya A., Fridlyand J., Jain A. N., Weinberg V., Kowbel D. et al. (2004) Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum. Mol. Genet. 13: 1303-1313
127. van de Vijver M. J., He Y. D., van't Veer L. J., Dai H., Hart A. A., Voskuil D. W. et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347: 1999-2009
128. van't Veer L. J., Dai H., van de Vijver M. J., He Y. D., Hart A. A., Mao M. et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536
129. Ramaswamy S., Ross K. N., Lander E. S. and Golub T. R. (2003) A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33: 49-54
130. Porter D. A., Krop I. E., Nasser S., Sgroi D., Kaelin C. M., Marks J. R. et al. (2001) A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 61: 5697-5702
131. Klein C. A., Blankenstein T. J., Schmidt-Kittler O., Petronio M., Polzer B., Stoecklein N. H. et al. (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360: 683-689
132. Sternlicht M. D., Bissell M. J. and Werb Z. (2000) The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 19: 1102-1113
133. Minn A. J., Gupta G. P., Siegel P. M., Bos P. D., Shu W., Giri D. D. et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524
134. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M. E. et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56
135. Yang J., Mani S. A., Donaher J. L., Ramaswamy S., Itzykson R. A., Come C. et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939
136. Douma S., Van Laar T., Zevenhoven J., Meuwissen R., Van Garderen E. and Peeper D. S. (2004) Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034-1039
137. Arthur W. T., Noren N. K. and Burridge K. (2002) Regulation of Rho family GTPases by cell-cell and cell-matrix adhesion. Biol. Res. 35: 239-246
138. Suwa H., Ohshio G., Imamura T., Watanabe G., Arii S., Imamura M. et al. (1998) Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br. J. Cancer 77: 147-152
139. Kondo T., Sentani K., Oue N., Yoshida K., Nakayama H. and Yasui W. (2004) Expression of RHOC is associated with metastasis of gastric carcinomas. Pathobiology 71: 19-25
140. Hakem A., Sanchez-Sweatman O., You-Ten A., Duncan G., Wakeham A., Khokha R. et al. (2005) RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev. 19: 1974-1979
141. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S. and Kuliopulos A. (2005) PARI is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303-313
142. Even-Ram S. C., Maoz M., Pokroy E., Reich R., Katz B. Z., Gutwein P. et al. (2001) Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J. Biol. Chem. 276: 10952-10962
143. Rickles F. R., Levine M. and Edwards R. L. (1992) Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 11: 237-248
144. Shi X., Gangadharan B., Brass L. F., Ruf W. and Mueller B. M. (2004) Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol. Cancer Res. 2: 395-402
145. Bhowmick N. A. and Moses H. L. (2005) Tumor-stroma interactions. Curr. Opin. Genet. Dev. 15: 97-101
146. Carmeliet P. and Jain R. K. (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
147. Folkman J. (2003) Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3: 643-651
148. Bergers G. and Benjamin L. E. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3: 401-410
149. Joyce J. A. (2005) Therapeutic targeting of the tumor microenviromnent. Cancer Cell 7: 513-520
150. Benoy I. H., Salgado R., Elst H., Van Dam P., Weyler J., Van Marck E. et al. (2005) Relative microvessel area of the primary tumour and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res. 7: R210-R219
151. Fukata S., Inoue K., Kamada M., Kawada C., Furihata M., Ohtsuki Y. et al. (2005) Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organspecific metastasis of renal cell carcinoma. Cancer 103: 931-942
152. Fox S. B., Gasparini G. and Harris A. L. (2001) Angiogenesis: pathological, prognostic and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2: 278-289
153. Guang-Wu H., Sunagawa M., Jie-En L., Shimada S., Gang Z., Tokeshi Y. et al. (2000) The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF) and the extension of nasopharyngeal carcinoma. Laryngoscope 110: 2066-2069
154. Huang S. P., Wu M. S., Wang H. P., Yang C. S., Kuo M. L. and Lin J. T. (2002) Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J. Gastroenterol. Hepatol. 17: 1165-1169
155. Tokunaga T., Nakamura M., Oshika Y., Abe Y., Ozeki Y., Fukushima Y. et al. (1999) Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br. J. Cancer 79: 354-359
156. Khanna C., Jaboin J. J., Drakos E., Tsokos M. and Thiele C. J. (2002) Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 16: 77-85
157. Rofstad E. K. and Halsor E. F. (2000) Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 60: 4932-4938
158. Stearns M. E., Garcia F. U., Fudge K., Rhim J. and Wang M. (1999) Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin. Cancer Res. 5: 711-720
159. Polnaszek N., Kwabi-Addo B., Peterson L. E., Ozen M., Greenberg N. M., Ortega S. et al. (2003) Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 63: 5754-5760
160. Nguyen M., Lee M. C., Wang J. L., Tomlinson J. S., Shao Z. M., Alpaugh M. L. et al. (2000) The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype. Oncogene 19: 3449-3459
161. Chen C. T., Lin J., Li Q., Phipps S. S., Jakubczak J. L., Stewart D. A. et al. (2000) Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum. Gene Ther. 11: 1983-1996
162. de Lorenzo M. S., Ripoll G. V., Yoshiji H., Yamazaki M., Thorgeirsson U. P., Alonso D. F. et al. (2003) Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In Vivo 17: 45-50
163. Gannon G., Mandriota S. J., Cui L., Baetens D., Pepper M. S. and Christofori G. (2002) Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res. 62: 603-608
164. Viloria-Petit A., Miquerol L., Yu J. L., Gertsenstein M., Sheehan C., May L. et al. (2003) Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogeneinduced tumors. EMBO J. 22: 4091-4102
165. Sauter E. R., Nesbit M., Watson J. C., Klein-Szanto A., Litwin S. and Herlyn M. (1999) Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin. Cancer Res. 5: 775-782
166. Nathanson S. D. (2003) Insights into the mechanisms of lymph node metastasis. Cancer 98: 413-423
167. Pepper M. S., Tille J. C., Nisato R. and Skobe M. (2003) Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 314: 167-177
168. Franchi A., Gallo O., Massi D., Baroni G. and Santucci M. (2004) Tumor
169. Dadras S. S., Paul T., Bertoncini J., Brown L. F., Muzikansky A., Jackson D. G. et al. (2003) Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am. J. Pathol. 162: 1951-1960
170. Alitalo K. and Carmeliet P. (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1: 219-227
171. Saharinen P., Tammela T., Karkkainen M. J. and Alitalo K. (2004) Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 25: 387-395
172. Jia Y. T., Li Z. X., He Y. T., Liang W., Yang H. C. and Ma H. J. (2004) Expression of vascular endothelial growth factor-C and the relationship between lymphangiogenesis and lymphatic metastasis in colorectal cancer. World J. Gastroenterol. 10: 3261-3263
173. Suzuki K., Morita T. and Tokue A. (2005) Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int. J. Urol. 12: 152-158
174. Kurahara H., Takao S., Maemura K., Shinchi H., Natsugoe S. and Aikou T. (2004) Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin. Cancer Res. 10: 8413-8420
175. Kawakami M., Furuhata T., Kimura Y., Yamaguchi K., Hata F., Sasaki K. et al. (2003) Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer. J. Exp. Clin. Cancer Res. 22: 229-237
176. Kitadai Y., Kodama M., Cho S., Kuroda T., Ochiumi T., Kimura S. et al. (2005) Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int. J. Cancer 115: 388-392
177. Krishnan J., Kirkin V., Steffen A., Hegen M., Weih D., Tomarev S. et al. (2003) Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res. 63: 713-722
178. Saharinen P. and Petrova T. V. (2004) Molecular regulation of lymphangiogenesis. Ann. N. Y. Acad. Sci. 1014: 76-87
179. Hanrahan V., Currie M. J., Gunningham S. P., Morrin H. R., Scott P. A., Robinson B. A. et al. (2003) The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J. Pathol. 200: 183-194
180. McCarron S. L., Edwards S., Evans P. R., Gibbs R., Dearnaley D. P., Dowe A. et al. (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 62: 3369-3372
181. Powell D. W., Mifflin R. C., Valentich J. D., Crowe S. E., Saada J. I. and West A. B. (1999) Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 277: C1-C9
182. Orimo A., Gupta P. B., Sgroi D. C., Arenzana-Seisdedos F., Delaunay T., Naeem R. et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348
183. Hayward S. W., Wang Y., Cao M., Hom Y. K., Zhang B., Grossfeld G. D. et al. (2001) Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 61: 8135-8142
184. De Wever O. and Mareel M. (2003) Role of tissue stroma in cancer cell invasion. J. Pathol. 200: 429-447
185. Elenbaas B. and Weinberg R. A. (2001) Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264: 169-184
186. Singh R. K., Bucana C. D., Gutman M., Fan D., Wilson M. R. and Fidler I. J. (1994) Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am. J. Pathol. 145: 365-374
187. Nakajima M., Morikawa K., Fabra A., Bucana C. D. and Fidler I. J. (1990) Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J. Natl. Cancer Inst. 82: 1890-1898
188. Bhowmick N. A., Chytil A., Plieth D., Gorska A. E., Dumont N., Shappell S. et al. (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851
189. Liang Z., Wu T., Lou H., Yu X., Taichman R. S., Lau S. K. et al. (2004) Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 64: 4302-4308
190. McClain K. L. (1997) Immunodeficiency states and related malignancies. Cancer Treat. Res. 92: 39-61
191. Lake R. A. and Robinson B. W. (2005) Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer 5: 397-405
192. Zou W. (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274
193. Lingen M. W. (2001) Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing. Arch. Pathol. Lab. Med. 125: 67-71
194. Nathan C. (2002) Points of control in inflammation. Nature 420: 846-852
195. Bottazzi B., Polentarutti N., Acero R., Balsari A., Boraschi D., Ghezzi P. et al. (1983) Regulation of the macrophage content of neoplasms by chemoattractants. Science 220: 210-212
196. Coussens L. M. and Werb Z. (2002) Inflammation and cancer. Nature 420: 860-867
197. Balkwill F. (2004) Cancer and the chemokine network. Nat. Rev. Cancer 4: 540-550
198. Bingle L., Brown N. J. and Lewis C. E. (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196: 254-265
199. Liss C., Fekete M. J., Hasina R., Lam C. D. and Lingen M. W. (2001) Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int. J. Cancer 93: 781-785
200. Skobe M., Hamberg L. M., Hawighorst T., Schirner M., Wolf G. L., Alitalo K. et al. (2001) Concurrent induction of lymphangiogenesis, angiogenesis and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol. 159: 893-903
201. Ohno S., Inagawa H., Dhar D. K., Fujii T., Ueda S., Tachibana M. et al. (2003) The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 23: 5015-5022
202. Shimura S., Yang G., Ebara S., Wheeler T. M., Frolov A. and Thompson T. C. (2000) Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 60: 5857-5861
203. Chen J. J., Lin Y. C., Yao P. L., Yuan A., Chen H. Y., Shun C. T. et al. (2005) Tumor-associated macrophages: the double-edged sword in cancer progression. J. Clin. Oncol. 23: 953-964
204. Dranoff G. (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4: 11-22
205. Gabrilovich D. I., Chen H. L., Girgis K. R., Cunningham H. T., Meny G. M., Nadaf S. et al. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2: 1096-1103
206. Gorelik L. and Flavell R. A. (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7: 1118-1122
207. Menetrier-Caux C., Montmain G., Dieu M. C., Bain C., Favrot M. C., Caux C. et al. (1998) Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92: 4778-4791
208. Balkwill F. (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13: 135-141
209. Xu W., Liu L. Z., Loizidou M., Ahmed M. and Charles I. G. (2002) The role of nitric oxide in cancer. Cell Res. 12: 311-320
210. O'Sullivan C., Lewis C. E., Harris A. L. and McGee J. O. (1993) Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 342: 148-149
211. Ruohola J. K., Viitanen T. P., Valve E. M., Seppanen J. A., Loponen N. T., Keskitalo J. J. et al. (2001) Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res. 61: 4229-4237
212. Nagy J., Curry G. W., Hillan K. J., McKay I. C., Mallon E., Purushotham A. D. et al. (1996) Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg. Oncol. 5: 15-21
213. Sunderkotter C., Steinbrink K., Goebeler M., Bhardwaj R. and Sorg C. (1994) Macrophages and angiogenesis. J. Leukoc. Biol. 55: 410-422
214. Leal J. A., Gangrade B. K., Kiser J. L., May J. V. and Keel B. A. (1991) Human mammary tumor cell proliferation: primary role of platelet-derived growth factor and possible synergism with human alpha-fetoprotein. Steroids 56: 247-251
215. Cursiefen C., Chen L., Borges L. P., Jackson D., Cao J., Radziejewski C. et al. (2004) VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113: 1040-1050
216. Schoppmann S. F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C. et al. (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161: 947-956
217. Maruyama K., Ii M., Cursiefen C., Jackson D. G., Keino H., Tomita M. et al. (2005) Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J. Clin. Invest. 115: 2363-2372
218. Coussens L. M., Tinkle C. L., Hanahan D. and Werb Z. (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490
219. Huang S., Van Arsdall M., Tedjarati S., McCarty M., Wu W., Langley R. et al. (2002) Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. 94: 1134-1142
220. van Netten J. P., Ashmead B. J., Parker R. L., Thornton I. G., Fletcher C., Cavers D. et al. (1993) Macrophage-tumor cell associations: a factor in metastasis of breast cancer? J. Leukoc. Biol. 54: 360-362
221. Jaiswal M., LaRusso N. F. and Gores G. J. (2001) Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G626-G634
222. Karre K., Ljunggren H. G., Piontek G. and Kiessling R. (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678
223. Smyth M. J., Thia K. Y., Street S. E., Cretney E., Trapani J. A., Taniguchi M. et al. (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191: 661-668
224. Colucci F., Di Santo J. P. and Leibson P. J. (2002) Natural killer cell activation in mice and men: different triggers for similar weapons? Nat Immunol. 3: 807-813
225. Whiteside T. L., Vujanovic N. L. and Herberman R. B. (1998) Natural killer cells and tumor therapy. Curr. Top. Microbiol. Immunol. 230: 221-244
226. Smyth M. J., Thia K. Y., Cretney E., Kelly J. M., Snook M. B., Forbes C. A. et al. (1999) Perform is a major contributor to NK cell control of tumor metastasis. J. Immunol. 162: 6658-6662
227. Hashimoto W., Takeda K., Anzai R., Ogasawara K., Sakihara H., Sugiura K. et al. (1995) Cytotoxic NK1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12. J. Immunol. 154: 4333-4340
228. Li C., Bai X., Wang S., Tomiyama-Miyaji C., Nagura T., Kawamura T. et al. (2004) Immunopotentiation of NKT cells by low-protein diet and the suppressive effect on tumor metastasis. Cell. Immunol. 231: 96-102
229. Smyth M. J., Hayakawa Y., Takeda K. and Yagita H. (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2: 850-861
230. Conejo-Garcia J. R., Benencia F., Courreges M. C., Kang E., Mohamed-Hadley A., Buckanovich R. J. et al. (2004) Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 10: 950-958
231. Zou W., Machelon V., Coulomb-L'Hermin A., Borvak J., Nome F., Isaeva T. et al. (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7: 1339-1346
232. Bell D., Chomarat P., Broyles D., Netto G., Harb G. M., Lebecque S. et al. (1999) In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190: 1417-1426
233. Troy A., Davidson P., Atkinson C. and Hart D. (1998) Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J. Urol. 160: 214-219
234. Troy A. J., Summers K. L., Davidson P. J., Atkinson C. H. and Hart D. N. (1998) Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4: 585-593
235. Yang L. and Carbone D. P. (2004) Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 92: 13-27
236. Lanzavecchia A. and Sallusto F. (2001) The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr. Opin. Immunol. 13: 291-298
237. Banchereau J. and Palucka A. K. (2005) Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5: 296-306
238. Curiel T. J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P. et al. (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9: 562-567
239. Iwai Y., Terawaki S. and Honjo T. (2005) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17: 133-144
240. Curiel T. J., Cheng P., Mottram P., Alvarez X., Moons L., Evdemon-Hogan M. et al. (2004) Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64: 5535-5538
241. Conejo-Garcia J. R., Buckanovich R. J., Benencia F., Courreges M. C., Rubin S. C., Carroll R. G. et al. (2005) Vascular leukocytes contribute to tumor vascularization. Blood 105: 679-681
242. Fallarino F., Grohmann U., Bianchi R., Vacca C., Fioretti M. C. and Puccetti P. (2000) Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. J. Immunol. 165: 5495-5501
243. Knutson K. L. and Disis M. L. (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54: 721-728
244. Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P. et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949
245. Matar P., Rozados V. R., Gonzalez A. D., Dlugovitzky D. G., Bonfil R. D. and Scharovsky O. G. (2000) Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur. J. Cancer 36: 1060-1066
246. Schirrmacher V. (2005) T cell-mediated immunotherapy of metastases: state of the art in 2005. Expert Opin. Biol. Ther. 5: 1051-1068
247. Gilboa E. (2004) The promise of cancer vaccines. Nat. Rev. Cancer 4: 401-411
248. Nyhus J. K., Wolford C. C., Friece C. R., Nelson M. B., Sampsel J. W. and Barbera-Guillem E. (2001) IgG-recognizing shed tumor-associated antigens can promote tumor invasion and metastasis. Cancer Immunol. Immunother. 50: 361-372
249. de Visser K. E., Korets L. V. and Coussens L. M. (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423